Press Releases - Wave Life Sciences
Oct 1, 2024 · Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs. Oct 16, 2024. Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency. Oct 16, 2024.
Wave Life Sciences Reports Third Quarter 2024 Financial Results …
1 day ago · Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website. About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a biotechnology ...
Wave Life Sciences
Sep 26, 2024 · Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping. Read more.
Wave Life Sciences Highlights Growing Pipeline at Research Day ...
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to ...
Wave Life Sciences Highlights Growing Pipeline at Research Day ...
Oct 30, 2024 · Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent ...
Wave Life Sciences Prices Upsized $200 Million Public Offering of ...
CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announced underwritten public offering of 23,125,001 of its ordinary shares at a ...
Wave Life Sciences Announces Positive Results from Phase 1b/2a …
CAMBRIDGE, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
Wave Life Sciences Highlights Recent Achievements and …
Jan 8, 2024 · In September 2023, Wave demonstrated the first in vivo proof-of-concept for INHBE silencing, with INHBE mRNA reduction in diet-induced obese mice well beyond the 50% therapeutic threshold,...
Wave Life Sciences Shares Surge After RNA Editing Discovery
Oct 17, 2024 · Wave's RNA editing technology appears to have highly potential for the treatment of AATD, a genetic disorder with potential life threatening and implicating the lungs and liver.
Wave Life Sciences Reports Second Quarter 2024 Financial …
CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...